Pharmova的美国单位扩大Spokane设施,投资300万美元,到2028年将无菌注射生产增加一倍。 Pharmova’s U.S. unit to expand Spokane facility with $300M investment, doubling sterile injectable production by 2028.

美国药厂计划在2028年扩建3亿美元, 将华盛顿斯波卡内(Spokane)的无菌注射制造翻倍, Jubilant Pharmova’s U.S. unit plans a $300 million expansion by 2028 to double sterile injectable manufacturing in Spokane, Washington, adding a third fill-and-finish line and boosting annual vial production to 100 million. 在预计全球无菌小瓶短缺7亿单位以及陆上生产需求增加的推动下,该项目包括1.5亿美元的美国政府赠款。 Driven by a projected 700 million-unit global shortfall in sterile vials and increased demand for onshore production, the project includes a $150 million U.S. government grant. 扩大后的设施每年可以提供近3.5亿个病人剂量,可能满足美国对药品和疫苗的大部分需求。 The expanded facility could supply nearly 350 million patient doses annually, potentially meeting a major portion of U.S. needs for medicines and vaccines.